BoA Merrill Lynch says that CSL is likely to launch a $900m-plus share buyback after it completes its $900 million buyback between August and October

BoA Merrill Lynch says that CSL is likely to launch a $900m-plus share buyback after it completes its $900 million buyback between August and October. Considering the blood plasma group's strong cash flow, a new buyback would need to be about $1.5 billion or the company's leverage ratio (net debt to EBITDA) would fall below the capital management policy range of 0.7 to 1.2 times. An alternative would be to use the cash for acquisitions, noting that M&A opportunities in China were a strategic must.


2 topics

Livewire News brings you a wide range of financial insights with a focus on Global Macro, Fixed Income, Currencies and Commodities.

Expertise

No areas of expertise

I would like to

Only to be used for sending genuine email enquiries to the Contributor. Livewire Markets Pty Ltd reserves its right to take any legal or other appropriate action in relation to misuse of this service.

Personal Information Collection Statement
Your personal information will be passed to the Contributor and/or its authorised service provider to assist the Contributor to contact you about your investment enquiry. They are required not to use your information for any other purpose. Our privacy policy explains how we store personal information and how you may access, correct or complain about the handling of personal information.

trending on livewire
Get the best of Livewire by signing up to our popular daily newsletter